Assessment of Lymphatic Drainage Through Sentinel Lymph Node Biopsy in Cutaneous Melanoma Using a Radioactive Tracer - Technetium-99m (99mTc).

cutaneous melanoma has often unpredictable lymphatic drainage patterns, especially at the level of the trunk, head and neck regions. Sentinel lymph node biopsy (SLNB) is an important prognostic tool that accurately assesses regional lymph node involvement and guides therapeutic decisions. Material and this prospective study involved 104 patients diagnosed with cutaneous melanoma who underwent SLNB using a radioactive tracer.

Axillary Reverse Mapping Using Indocyanine Green and Concurrent Sentinel Lymph Node Biopsy in Breast Cancer Patients with or without Neoadjuvant Systemic Treatment.

the axillary reverse mapping (ARM) procedure aims to preserve the lymphatic drainage structures of the upper extremity during axillary surgery for breast cancer, thereby reducing the risk of lymphedema in the upper limb. Material and this prospective study included 57 patients with breast cancer who underwent SLNB and ARM. The sentinel lymph node (SLN) was identified using a radioactive tracer.

The First Romanian Robotic-Assisted Mastectomy: A Starting Point for a Literature Review.

The advancements in the field of robotic surgery have led to its use in breast surgery. We report the first robotic-assisted nipple-sparing mastectomy (RNSM) using the da Vinci Xi surgical system, in Romania, for a patient with contralateral breast cancer. Immediate breast reconstruction was performed using a silicone implant.

Use of a Tumor Bed Boost in the Radiotherapy after Oncoplastic Breast Conserving Surgery.

Use of a radiotherapy (RT) tumor bed boost in addition to whole breast irradiation (WBI) after oncoplastic breast conserving surgery (OBCS) can be very challenging due to the massive tissue displacements. The aim of our study is to present relevant RT data regarding the use of a boost RT in patients who underwent OBCS and received adjuvant RT at Neolife Medical Center Bucharest. 12 patients treated with intensity modulated radiotherapy (IMRT), after OBCS, using conventional or hypofractionated schedules, between 10/2018 and 12/2020 were included in the study.

Pathological Response and Survival after Neoadjuvant Therapy for Her-2 Positive Breast Cancer.

Pathological complete response (pCR) after neoadjuvant systemic treatment represents a good surrogate marker for the prognosis of Her-2 positive Breast Cancer (BCs). The results improved after adding anti-Her-2 therapy to chemotherapy in neoadjuvant setting. Our retrospective study enrolled a cohort of 56 invasive Her-2 positive non-metastatic BCs treated with neoadjuvant systemic therapy between 2001 and 2018.